PolySciTech's SpinSwiper Could Speed Up Production of Controlled-Release Microparticles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PolySciTech's SpinSwiper Could Speed Up Production of Controlled-Release Microparticles


PolySciTech’s new launch, SpinSwiper, has the potential to speed up microparticle production. Researchers in academic, commercial and pharmaceutical settings who need to generate microparticles, including those used in controlled-release drug delivery, could benefit from this new product.

Current methods to produce microparticles have drawbacks, noted John Garner, manager of PolySciTech, in a press release. Garner explained that some processes produce particles of different sizes, which consequently affect drug release from the particles because smaller particles will release the drug faster than larger ones. Other processes create particles that adhere to the template, which makes them difficult to remove.

According to Garner, the SpinSwiper process to create microparticles is visually similar to filling the wells in an ice cube tray. "A disposable template that is made of water-soluble polymer and contains a series of micrometer-sized wells is placed on the SpinSwiper. The template rotates across a hollow swiping blade filled with polymer, a drug and a solvent. The blade pushes the solution into the wells and removes the excess as the template continues to rotate," he said. "When the polymer dries, the microparticles have been formed and are the same diameter and shape as the wells. The template is dissolved, which leaves the microparticles to be collected."

Garner added that the microparticle technology, introduced in the late 1980s, may advance and new formulations may be developed with the SpinSwiper tool. "There may be such a small number of microparticle formulations because it is not easy to maintain consistency of conventional methods of preparation in scaled-up manufacturing," he said. "SpinSwiper allows researchers to design and produce formulations fast in quantities large enough for in vitro characterization and in vivo studies. A formulation can be adjusted easily to obtain the desired release kinetics matching that of a clinical product." 

Source: Purdue University Research Park News

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here